Wnt Signaling and Bone Mass Regulation

Wnt signalling comprises a family of secreted glycoproteins that orchestrate bone formation, remodelling and homeostasis through tightly regulated molecular cascades. In the canonical pathway, Wnt ligands bind Frizzled receptors and LRP5/6 co-receptors on osteoblasts, stabilising β-catenin and promoting transcription of genes essential for osteoblast proliferation, differentiation and survival. Non-canonical Wnt pathways modulate cytoskeletal organisation, cell polarity and calcium flux, influencing osteocyte responses to mechanical strain and the coupling of bone formation to resorption. Negative regulators such as sclerostin, DKK1 and secreted frizzled-related proteins fine-tune signalling intensity to maintain skeletal integrity. Genetic mutations that enhance Wnt activity yield high-bone-mass phenotypes, whereas loss-of-function alleles precipitate osteoporosis and reduced fracture resistance. Mechanical loading engages Wnt/β-catenin signalling to adapt bone architecture to functional demands, while aberrant pathway activation underlies rare sclerosing bone dysplasias. Pharmacological modulation—ranging from sclerostin-neutralising antibodies to porcupine inhibitors—has emerged as a promising strategy to treat osteoporosis and high-bone-mass disorders. The global burden of skeletal fragility and the growing elderly population underscore the importance of targeting Wnt signalling to improve bone health and mobility worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Wnt Signaling and Bone Mass Regulation publication trend

The graph below shows the total number of articles in wnt signaling and bone mass regulation across all publications each year (not limited to Nature Index journals).

Technical terms

Wnt ligand: A secreted glycoprotein that initiates Wnt signalling by binding to Frizzled and LRP5/6 receptors on target cells.

Frizzled receptor: A seven-transmembrane protein that recognises Wnt ligands and transduces signals to intracellular cofactors.

LRP5/6: Low-density lipoprotein receptor-related proteins that act as co-receptors in the canonical Wnt pathway.

β-catenin: An intracellular mediator whose stabilisation and nuclear translocation drive transcription of Wnt target genes.

Porcupine: An endoplasmic reticulum–resident O-acyltransferase critical for Wnt ligand palmitoylation and secretion.

Sclerostin (SOST): A glycoprotein produced by osteocytes that inhibits Wnt signalling by binding to LRP5/6.

Osteoblast: A bone-forming cell responsible for synthesising bone matrix and regulating mineralisation.

Osteoclast: A multinucleated cell that resorbs bone during remodelling, facilitating renewal of skeletal tissue.

References

1. Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5. Bone Research (2023).
2. WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders. Frontiers in Endocrinology (2020).
3. Evolutionary and functional analyses of LRP5 in archaic and extant modern humans. Human Genomics (2024).
4. Wnt/β-Catenin Signaling Is a Normal Physiological Response to Mechanical Loading in Bone*. Journal of Biological Chemistry (2006).